Other medications (sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, or GLP-1 RAs), with or without metformin, are appropriate initial therapy for individuals with T2DM or individuals at high risk of atherosclerotic CVD, heart failure, or chronic kidney disease. Here, GLP1R is linked to heart failure.